Table 1.

Biomarkers and associate drugs by category.

BIOMARKER	THERAPEUTIC IMPLICATIONS	BRAND NAME	NCCN GUIDELINES	NCCN COMPENDIUM	FDA-APPROVED LABELING
					LUNG	WITH BIOMARKER
Category A	Known biomarker; FDA-approved biomarker-related drug for lung cancer
EGFR mutation	Erlotinib	Tarceva	x	x	x	x
	Gefitinib	Iressa			x
	Afatinib	Gilotrif	x		x	x
ALK translocation	Crizotinib	Xalkori	x	x	x	x
Category B	Biomarker unknown or not approved by FDA; FDA-approved drug for lung cancer
	Bevacizumab	Avastin	x	x	x
	Carboplatin	Generic	x	x	x
EGFR expression	Cetuximab	Erbitux	x	x	x
ERCC1	Cisplatin	Generic	x	x	x
ROS1	Crizotinib	Xalkori
	Docetaxel	Taxotere	x	x	x
	Erlotinib	[see above]	x	x
	Etoposide	Generic	x	x	x
RRM-1	Gemcitabine	[see above]	x
	Ifosfamide	Ifex	x	x
	Irinotecan	Camptosar	x	x	x
	Mesna	Generic		x
	Mitomycin	Generic	x	x
PDL-1	Nivolumab	Opdivo
	Paclitaxel	Generic	x	x	x
	Pemetrexed	[see above]	x
	Vinblastine	Generic	x	x	x
	Vinorelbine	Navelbine	x		x
Category C	Potential biomarker, no FDA-approved drug available
MEK1 mutation
PIK3ca, AKT1, PTEN alterations
FGFR1 amplifications
Beta-catenin mutation